Cost-Utility Analysis Of Enzalutamide For Patients With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer (Mcrpc) After Failure Of Androgen Deprivation Therapy (Adt)
Abstract
Authors
C Vicente A Loblaw S North W Kassouf S Naidoo F Husein HR Nakhaipour